Partnership between Medtronic and CareLine Solutions

Partnership between Medtronic and CareLine Solutions

by | 25 Oct. 21 | Corporate

A unique partnership in the medical devices

CareLine Solutions is proud to announce its partnership with Medtronic, a world leader in cardiac devices, improving the heart failure care pathway.

Headquartered in Dublin, Ireland, Medtronic is a world leader in medical technology, services and solutions. Medtronic employs over 90.000 people in the word, servicing physicians, hospitals and patients in over 150 countries. The company is committed to work together with partners across the world to advance healthcare together.

This partnership completes our heart failure remote monitoring solution further. In addition to clinical parameters, blood samples and symptoms, the CareLine platform now integrates data transmitted by Medtronic cardiac implanted electrical devices (pacemakers and defibrillators) such as patient activity, indicators of pulmonary volume overload and arrhythmias. The healthcare professional may choose which alerts to receive for each patient.

As stated by Florence Dupré, president of Medtronic France, “ This partnership enables to offer the various heart failure professionals, a highly qualitative solution to ensure optimal care of patients with heart failure”.

Our shared goal is to optimize outpatient management and to improve medical support through innovative technology. Our mission is to identify patients at risk of cardiac decompensation more quickly and to avoid hospitalization by promoting management at the patient’s home, which will also reduce hospitalization costs for healthcare institutions.

Pacemaker remote monitoring

Pacemaker remote monitoring

by | 21 Sep. 21 | Scientific publications

Twenty years ago, pacemakers were the first implantable cardiac devices to offer automated remote monitoring. This innovation was particularly well received by patients. However, for many healthcare professionals, this type of care still appears optional, despite benefits comparable to those of ICD remote monitoring, which are reviewed in the article Remote monitoring of pacemakers, published in Archives of Cardiovascular Disease.

Remote monitoring reduces the number of consultations and lightens the healthcare teams’ workload. The ability to detect technical or clinical complications early on increases patient safety and improves the management of safety recalls.

The reduction in hospitalizations and deaths associated with pacemaker remote monitoring is comparable to that observed with ICD remote monitoring in a very large observational cohort. This evidence-based literature review therefore concludes on the necessary recognition and systematic use of pacemaker remote monitoring.

These extensive benefits indicate that Remote Monitoring should not be denied to pacemaker recipients.

The full article is available here (open access).

Remote monitoring during the first COVID-19 lockdown in France

Remote monitoring during the first COVID-19 lockdown in France

by | 29 Apr. 21 | Scientific publications

During the first French national lockdown due to COVID-19, the provision of conventional care was drastically reduced: -58% of medical contacts, -77% in cardiology.

However, the lockdown had little or no impact in the short term on the vital parameters and clinical status of patients with heart failure benefiting from multiparametric remote monitoring performed by the Bordeaux University Hospital, as shown in the article Remote monitoring of patients with heart failure during the first national lockdown for COVID-19 in France, published in the European Heart Journal – Digital Health.

The clinical status of HF patients under multiparametric remote monitoring was minimally affected by lockdown restrictions despite a marked decrease in conventional measures of healthcare use. This strategy, combined with patient education, may mitigate the health risks associated with strict lockdowns for COVID-19.

This management strategy enabled early identification and home management of most decompensated heart failure events during this lockdown.

Our findings suggest that a combination of home sensors and CIED remote interrogation capabilities represent a method of complying with public health measures while preserving the care and safety of patients with chronic HF. Our experience therefore argues for the benefits of this strategy in this patient population and supports larger studies to confirm our findings.

The full article is available here (open access).

TIM-HF2

TIM-HF2

by | 25 Aug. 18 | Scientific publications

The Telemedical Interventional Management in Heart Failure II (TIM-HF2) clinical study1, published in The Lancet, is a prospective, multicenter, randomised study comparing a strategy for remote management of heart failure patients using multiparametric telemonitoring performed by an integrated medical team (Telemedical Center) to conventional care. Thanks to its rigorous design2, it is considered a landmark study:

To the best of our knowledge, this is the first RCT [Randomised Controlled Trial] to use a structured remote patient management intervention that was designed to be a true holistic approach for the management of patients with heart failure, involving cardiologists, general practitioners, nurses, other health-care providers, and the patient.

The study included 1,571 patients who were randomized and followed up for at least 365 days, with a maximum of 393 days. The remote management strategy was based on:

  • Remote monitoring of data including weight, blood pressure, cardiac data (heart rate, ECG), saturation and a self-assessment questionnaire;
  • Daily data collection using connected devices made available to patients;
  • Enrollment of patients in a therapeutic education program.

Results demonstrate a statistically significant reduction in the number of days lost due to all-cause death or unplanned cardiovascular hospital admission in the remote management group. They establish a new standard for remote management of heart failure:

The TIM-HF2 trial suggests that a structured remote patient management intervention, when used in a well defined heart failure population, could reduce the percentage of days lost due to unplanned cardiovascular hospital admissions and all-cause mortality.

The CareLine platform architecture was designed drawing on this experience in order to enable remote management providing clinical and medico-economic benefits.

Find the full study here.

1. Clinical study NCT01878630 (ClinicalTrials.gov)

2. The complete study protocol is available here.